Vaccine composition containing synthetic adjuvant
AssigneeInfectious Disease Research Institute
InventorsSteven G. Reed, Darrick Carter
Life of this patent
Estimating the term…
Abstract
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
Claims20
A vaccine composition comprising:
- (a) an antigen;
- (b) a pharmaceutically acceptable carrier or excipient, and
- (c) a lipid adjuvant of the formula:
- wherein:
- R1, R3, R5 and R6 are undecyl;
- and
- R2 and R4 are tridecyl;
- or a pharmaceutically acceptable salt thereof.
A kit, comprising:
- (a) an adjuvant composition in a first container, the adjuvant composition comprising a pharmaceutically acceptable carrier or excipient, and a compound of the formula:
- wherein:
- R1, R3, R5 and R6 are undecyl;
- and
- R2 and R4 are tridecyl;
- or a pharmaceutically acceptable salt thereof;
- and
- (b) an antigen in a second container, wherein the adjuvant composition is not in contact with the antigen.
Dependencies are inferred from the claim text.